Occult prostate cancer effects the results of case-control studies due to verification bias

Anticancer Research

Volumn 28, Issue 5 B, 2008, Pages 3007-3010

  Iguchi, Taro ^a,b   Wang, Ching Y ^a   Delongchamps, Nicolas B ^a   Sunheimer, Robert ^a   Nakatani, Tatsuya ^b   De La Roza, Gustavo ^a   Haas, Gabriel P ^a  

^a State University of New York Upstate Medical University: College of Medicine   (United States)

^b OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Autopsy; Occult cancer; Polymorphisms; Prostate cancer; Prostate specific antigen

Indexed keywords

MANGANESE SUPEROXIDE DISMUTASE; PROSTATE SPECIFIC ANTIGEN;

ARTICLE; AUTOPSY; CANCER GROWTH; DNA POLYMORPHISM; GENE FREQUENCY; GENOTYPE; HISTOPATHOLOGY; HUMAN; OCCULT CANCER; PRIORITY JOURNAL; PROSTATE CANCER;

BIAS (EPIDEMIOLOGY); CASE-CONTROL STUDIES; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROSTATIC NEOPLASMS; SUPEROXIDE DISMUTASE;

EID: 55749098998     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Bates AS, Margolis PA and Evans AT: Verification bias in pediatric studies evaluating diagnostic tests. J Pediatr 122: 585-590, 1993.
2. Punglia RS, D'Amico AV, Catalona WJ, Roehl KA and Kuntz KM: Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen. N Engl J Med 349: 335-342, 2003.
3. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, Minasian LM, Ford LG, Lippman SM, Crawford ED, Crowley JJ and Coltman CA Jr: Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med 350: 2239-2246, 2004.
4. Haas GP, Delongchamps NB, Jones RF, Chandan V, Serio AM, Vickers AJ, Jumbelic M, Threatte G, Korets R, Lilja H and de la Roza G: Needle biopsies on autopsy prostates: sensitivity of cancer detection based on true prevalence. J Natl Cancer Inst 99: 1484-1489, 2007.
5. Haas GP, Delongchamps N, Brawley OW, Wang CY and de la Roza G: The worldwide epidemiology of prostate cancer: perspectives from autopsy studies. Can J Urol 15: 3866-3871, 2008.
6. Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M, Pukkala E, Skytthe A and Hemminki K: Environmental and heritable factors in the causation of cancer-analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 343: 78-85, 2000.
7. Carter BS, Beaty TH, Steinberg GD, Childs B and Walsh PC: Mendelian inheritance of familial prostate cancer. Proc Natl Acad Sci USA 89: 3367-3371, 1992.
8. Di Paolo OA, Teitel CH, Nowell S, Coles BF and Kadlubar FF: Expression of cytochromes P450 and glutathione-S-transferases in human prostate, and the potential for activation of heterocyclic amine carcinogens via acetyl-CoA-, PAPS- and ATP-dependent pathways. Int J Cancer 117: 8-13, 2005.
9. Giovannucci E, Liu Y, Platz EA, Stampfer MJ and Willett WC: Risk factors for prostate cancer incidence and progression in the health professionals' follow-up study. Int J Cancer 121: 1571-1578, 2007.
10. Gong Z, Agalliu I, Lin DW, Stanford JL and Kristal AR: Cigarette smoking and prostate cancer-specific mortality following diagnosis in middle-aged men. Cancer Causes Control 19: 25-31, 2008.
11. Wright ME, Chang SC, Schatzkin A, Albanes D, Kipnis V, Mouw T, Hurwitz P, Hollenbeck A and Leitzmann MF: Prospective study of adiposity and weight change in relation to prostate cancer incidence and mortality. Cancer 109: 675-684, 2007.
12. Iguchi T, Wang CY, Delongchamps NB, Sunheimer R, Nakatani T, de la Roza G and Haas GP: Association of prostate cancer and manganese superoxide dismutase AA genotype is influenced by the presence of occult cancer in the control group. Urol, in press.
13. Choi JY, Neuhouser ML, Barnett M, Hudson M, Kristal AR, Thornquist M, King IB, Goodman GE and Ambrosone CB: Polymorphisms in oxidative stress-related genes are not associated with prostate cancer risk in heavy smokers. Cancer Epidemiol Biomarkers Prev 16: 1115-1120, 2007.
14. Woodson K, Tangrea JA, Lehman TA, Modali R, Taylor KM, Snyder K, Taylor PR, Virtamo J and Albanes D: Manganese Superoxide dismutase (MnSOD) polymorphism, alpha-tocopherol supplementation and prostate cancer risk in the alpha-tocopherol, beta-carotene cancer prevention study (Finland). Cancer Causes Control 14: 513-518, 2003.
15. Li H, Kantoff PW, Giovannucci E, Leitzmann MF, Gaziano JM, Stampfer MJ and Ma J: Manganese superoxide dismutase polymorphism, prediagnostic antioxidant status, and risk of clinical significant prostate cancer. Cancer Res 65: 2498-2504, 2005.
16. Kang D, Lee KM, Park SK, Berndt SI, Peters U, Reding D, Chatterjee N, Welch R, Chanock S, Huang WY and Hayes RB: Functional variant of manganese superoxide dismutase (SOD2 V16A) polymorphism is associated with prostate cancer risk in the prostate, lung, colorectal, and ovarian cancer study. Cancer Epidemiol Biomarkers Prev 16: 1581-1586, 2007.
17. Jemal A, Siegel R, Ward E, Murray T, Xu J and Thun MJ: Cancer statistics, 2007. CA Cancer J Clin 57: 43-66, 2007.
18. Reiter RE and de Kernion JB. Epidemiology, etiology, and prevention of prostate cancer. In: Campbell's Urology IV. PC Walsh, AB Retik, ED Vaughan, AJ Wein, LR Kavoussi, AC Novick, AW Partin and CA Peters (eds.). Readfield, ME, Saunders, pp. 3003-3024, 2002.
19. Bostwick DG, Pacelli A and Lopez-Beltran A: Molecular biology of prostatic intraepithelial neoplasia. Prostate 29: 117-134, 1996.
20. Holmberg L, Bill-Axelson A, Helgesen F, Salo JO, Folmerz P, Haggman M, Andersson SO, Spangberg A, Busch C, Nordling S, Palmgren J, Adami HO, Johansson JE and Norlen BJ: A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med 347: 781-789, 2002.
21. Adolfsson J, Tribukait B and Levitt S: The 20-yr outcome in patients with well- or moderately differentiated clinically localized prostate cancer diagnosed in the pre-PSA era: the prognostic value of tumour ploidy and comorbidity. Eur Urol 52: 1028-1035, 2007.
22. Dunn JE: Cancer epidemiology in populations of the United States-with emphasis on Hawaii and California-and Japan. Cancer Res 35: 3240-3245, 1975.
23. Jones RF, Sunheimer R, Friedman H, Miller D, Ginsburg R, Jumbelic M, Threatte G and Haas GP: Comparison of ante- and post-mortem PSA levels for epidemiological studies. Anticancer Res 25: 1263-1267, 2005.
24. Thompson IM, Ankerst DP, Chi C, Lucia MS, Goodman PJ, Crowley JJ, Parnes HL and Coltman CA Jr: Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA 294: 66-70, 2005.